Use to assess and monitor IgA basement membrane zone antibodies in patients with linear IgA disease, including linear IgA bullous dermatosis and chronic bullous disease of childhood, and IgA variant epidermolysis bullosa acquisita (EBA). Testing should be correlated with concurrent Direct Immunofluorescence, Tissue Biopsy (Cutaneous, Mucosal, Epithelial) (0092572).
For initial linear IgA disease diagnosis, serum Basement Membrane Zone Antibody Panel (3001410) or Immunobullous Disease Antibody Panel (3001409) is preferred and offers a more comprehensive evaluation.
For more information about components, methodology, and specimen type, see the ARUP Immunobullous Disease Testing Comparison tool.
Semi-Quantitative Indirect Immunofluorescence (IIF)
New York DOH Approval Status
Plain red or serum separator tube (SST).
Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Hemolyzed or lipemic specimens. Plasma.
Ambient: 1 week; Refrigerated: 2 weeks; Frozen: Indefinitely
Refer to report
Performed by non-ARUP Laboratory
For specimens less than 0.5 mL, call the Immunodermatology Laboratory at (866) 266-5699.
|Component Test Code*||Component Chart Name||LOINC|
|0092057||Epithelial BMZ Ab, IgA|
- atypical epithelial antibody-associated disease
- basement membrane zone antibody-associated disease
- childhood immunobullous disease
- chronic bullous disease of childhood
- epithelial antibody-associated disease
- Epithelial Basement Membrane Zone Antibody IgA
- hemidesmosomal protein antibodies
- hemidesmosome antibodies
- IgA variant epidermolysis bullosa acquisita (EBA)
- IgG/IgA basement membrane zone antibodies
- immunobullous disease of childhood
- indirect fluorescence assay
- indirect fluorescent antibody (IFA)
- indirect immunofluorescent assay
- linear IgA bullous dermatosis
- linear IgA disease
- linear IgG/IgA bullous dermatosis
- mixed epithelial antibody-associated disease
- mixed immunobullous disease of childhood
- salt-split skin test
- subepithelial immunobullous disease